1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Related Products (116):

Cat. No. Product Name Effect Purity
  • HY-101952
    Prostaglandin E2 Activator 98.36%
    Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
  • HY-B0131
    Prostaglandin E1 Agonist >98.0%
    Prostaglandin E1 (PGE1) is a potent vasodilator and activates the prostaglandin E1 (EP) receptor.
  • HY-103088
    E7046 Antagonist 99.60%
    E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
  • HY-50901
    ONO-AE3-208 Antagonist 98.65%
    ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
  • HY-16781
    Grapiprant Antagonist 99.68%
    Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment[3] .
  • HY-108566
    U-46619 Agonist >99.0%
    U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist.
  • HY-101438
    Darbufelone Inhibitor >98.0%
    Darbufelone is a dual inhibitor of cellular PGF and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50= 0.19 μM) but is much less potent with PGHS-1 (IC50=20 μM).
  • HY-133123
    EP4 receptor antagonist 1 Antagonist
    EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors.
  • HY-A0096
    Iloprost Agonist 99.06%
    Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.
  • HY-18966
    PF-04418948 Antagonist 99.22%
    PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.
  • HY-10418
    AH 6809 Antagonist 99.47%
    AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.
  • HY-14870
    Selexipag Agonist 99.93%
    Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
  • HY-B0577
    Latanoprost Agonist 99.83%
    Latanoprost (PHXA41) is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).
  • HY-16763
    Asapiprant Antagonist 99.67%
    Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.
  • HY-108912
    RO1138452 Antagonist 98.21%
    RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pKi is 9.3±0.1; in a recombinant IP receptor system, pKi is 8.7±0.06.
  • HY-16768
    Fevipiprant Antagonist 99.63%
    Fevipiprant (QAW039; NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.
  • HY-14839
    Evatanepag Agonist 99.80%
    Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.
  • HY-50175
    Laropiprant Antagonist 99.21%
    Laropiprant is a potent, selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.
  • HY-79593
    MRE-269 Agonist 99.46%
    MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
  • HY-10413
    MK-2894 Antagonist 98.10%
    MK-2894 is a highly potent and selective second generation EP4 antagonist.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.